NCT03855306View on ClinicalTrials.gov

A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2018

Primary Completion Date

July 7, 2018

Study Completion Date

August 15, 2018

Conditions

Healthy

Interventions

DRUG

Glibesyn

1 tablet contains 5 mg Glibenclamide

DRUG

Daonil

1 tablet contains 5 mg Glibenclamide

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

All Listed Sponsors

collaborator

Medochemie LTD Cyprus

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT03855306 - A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. ) | Biotech Hunter | Biotech Hunter